Posted by Michael Wonder on 05 Jul 2016
Biogen and AbbVie’s once-monthly Zinbryta (daclizumab) approved in European Union for treatment of multiple sclerosis
5 July 2016 - Zinbryta significantly reduced multiple measures of disease activity in patients with relapsing forms of multiple sclerosis.
The European Commission has granted marketing authorization for Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis, Biogen and AbbVie announced today. Zinbryta is a once-monthly, self-administered, subcutaneous injection.
